Northern Trust Corp lowered its position in SIGA Technologies, Inc. (OTCMKTS:SIGA) by 1.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 570,355 shares of the biotechnology company’s stock after selling 10,807 shares during the quarter. Northern Trust Corp owned about 0.71% of SIGA Technologies worth $4,505,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Citigroup Inc. grew its holdings in shares of SIGA Technologies by 11.9% in the fourth quarter. Citigroup Inc. now owns 22,110 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,358 shares during the period. BB&T Securities LLC purchased a new stake in shares of SIGA Technologies in the fourth quarter valued at about $81,000. Algert Global LLC purchased a new stake in shares of SIGA Technologies in the fourth quarter valued at about $85,000. Virtu Financial LLC purchased a new stake in shares of SIGA Technologies in the fourth quarter valued at about $119,000. Finally, ClariVest Asset Management LLC purchased a new stake in shares of SIGA Technologies in the fourth quarter valued at about $144,000. 6.66% of the stock is owned by hedge funds and other institutional investors.

OTCMKTS SIGA opened at $5.31 on Monday. SIGA Technologies, Inc. has a 12 month low of $4.68 and a 12 month high of $8.47.

WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/northern-trust-corp-reduces-stake-in-siga-technologies-inc-siga/2980525.html.

SIGA Technologies Company Profile

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

See Also: Closed-End Mutual Funds

Want to see what other hedge funds are holding SIGA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SIGA Technologies, Inc. (OTCMKTS:SIGA).

Institutional Ownership by Quarter for SIGA Technologies (OTCMKTS:SIGA)

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.